Fig. 1: Mouse model for Dox-inducible NANOG expression in skeletal muscle.
From: Skeletal muscle reprogramming enhances reinnervation after peripheral nerve injury
A Localized NANOG expression in the muscle was achieved by subcutaneous implantation of the slow-release polymer Elvax (shown in blue) near the TA, EDL, Soleus and Gastrocnemius muscles. Schematic of muscle adapted from123. Figure created with BioRender.com. B Image showing two pieces of Elvax implanted in the mouse leg. Piece 1 induces Dox/DMSO delivery to the TA and EDL muscle. Piece 2 induces Dox/DMSO delivery to the GA and Sol muscles. C Fold change in relative mRNA levels of NANOG from isolated TA muscle 4 days after Elvax implantation in naïve uninjured WT and NANOG animals (n = 3 biological replicates, normalized to WT; no Elvax). Statistical test performed is two-way ANOVA with Uncorrected Fisher’s LSD test. D Immunostaining of TA muscle sections for NANOG (red), Laminin (green) and DAPI (Blue) 4 days after DMSO-Elvax or Dox-Elvax implantation. Scale bar = 50 µm. Fields of view depict representative images from the center of the muscle and section adjacent to Elvax placement. E Western blot for NANOG in TA, GA, EDL and Sol muscles 4 days after DMSO-Elvax and Dox-Elvax implantation. Fold change in NANOG expression in Dox-Elvax compared to DMSO-Elvax quantified after normalization to GAPDH in (F) TA (G) GA (H) EDL and (I) Sol muscles; n = 3 biological replicates for both DMSO-Elvax and Dox-Elvax. For G-I, unpaired t-test used for statistical analysis. All data are presented as Mean ± SEM. Source data are provided as a Source Data file.
